Types segmentation categorizes FDA Grade Weight‑Loss Devices by engineering principle and delivery modality, thereby clarifying competitive dynamics and cost structures. Intragastric balloons represent the largest type, accounting for roughly 40 % of device shipments; their single‑use design and endoscopic placement generate modest unit costs but require periodic replacement, influencing recurring revenue streams. Gastric electrical stimulation systems, comprising implantable pulse generators and electrode arrays, hold a 30 % share and are distinguished by higher capital expenditure and longer service life, which concentrates revenue in the hospital‑acquisition phase. Endoscopic suturing platforms, used to create restrictive gastric folds, contribute about 20 % of the market; their reusable architecture yields lower per‑procedure cost but depends on operator expertise, affecting adoption velocity. The remaining 10 % consists of emerging neuro‑hormonal modulators that integrate drug‑delivery with device architecture, reflecting early‑stage R&D investment. In 2025, type‑level sales approximated $1.2 billion, with intragastric balloons generating $480 million, gastric electrical stimulation $360 million, endoscopic suturing $240 million, and neuro‑hormonal modulators $120 million. This distribution illustrates how device architecture drives both market share and revenue concentration within the overall market taxonomy.
